Drugs in the Pipeline
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
The approval was based on data from the SORAYA trial.
Drug Monograph Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
Alymsys is a vascular endothelial growth factor inhibitor.
Vegzelma is a vascular endothelial growth factor inhibitor.